Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib re-treatment in HER2-positive recurrent or metastatic breast cancer
ISRCTN93654271Phase 4Completed
- Sponsor
- The Second Xiangya Hospital
- Start
- Sep 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by The Second Xiangya Hospital. Primary endpoints: Progression-free survival on first pyrotinib treatment and Progression-free survival on pyrotinib re-treatment. Started Sep 2023; status: completed.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN93654271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN93654271.